Termeer speaks up on Genzyme sale price

Henri Termeer (photo) isn't totally opposed to selling Genzyme. He's opposed to Sanofi-Aventis' $69-per-share, $18.5 billion bid. That's the word in several media interviews. "The company is not for sale at $69 a share," Termeer tells Reuters. "What the shareholders deserve is a fair value," he said in a Bloomberg interview.

To hear Termeer read the tea leaves, Sanofi will eventually recognize that value--and the deal will get done via negotiations, not a hostile bid. "I think a hostile situation is unlikely to occur here," he explains to Reuters. "We need each other too much in terms of future value."

Indeed. Sanofi will need buy-in from Genzyme's leadership to make an acquisition pay off; the French drugmaker may have the manufacturing expertise to help effect Genzyme's ongoing manufacturing overhaul, but key managers and employee morale are important, too. And Termeer sounds as if he's looking to cap off his career in style: If he has to go out with a big M&A deal, then it had better be the biggest possible.

- read the Reuters interview
- get more from the Boston Globe
- see the Bloomberg profile

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.